Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shot in the dark: July 28, 2022.
A possible explanation may be related to the fact that physicians routinely take advantage of opportunities to be listed as authors, presenters, or contributors on articles, conferences, etc. for the sake of the recorded achievement.
HL, are you sure? I think the buying BP shareholders would certainly be made aware of future estimated earnings prior to any BO proxy vote. Who wouldn’t support a BO price that’s much higher than the usual multipliers when they’re being informed that the transaction is estimated to increase the BP share price by even higher multiples. If ever there were an exception to a rule, NWBO fits the bill considering the DCVax platform’s potential and the likelihood of it being part of SOC for many types of cancers.
scotty, this isn't a sewing circle.
I’m still here. I got a little lucky on this one, which doesn’t happen often, as I sold at a small loss after the PR about the BLA submission didn’t move the SP much. I had plans to get back in closer to FDA approval, and if a BO were to be announced prior, I was prepared to miss out on it. Now I just see this as a delayed entry point date. I can identify with those who are holding as I’ve been in NWBO for a very long time.
The elephant in the room.
The journal may be allowing the same NYAS presentation if it has been coordinated in advance.
Does MHRA publish a list of companies that have submitted BLAs and their statuses?
Good for you! I’ve seen practicing physicians testify on Capital Hill and elsewhere as to the efficacy of HCQ and Ivermectin in treating COVID-19.
Fair enough. I still see a gold-plated park bench in your future.
:) Just one additional comment, PM: current CFO topic aside, I recall NWBO being delisted from NASDAQ as a direct result of their low SP and not any governance issues.
Could it be that MRK doesn't publicize the NWBO combo trial at UCLA because that would positively impact NWBO's share price and would result in MRK negotiating against themselves for buying NWBO out at the lowest possible price. One can dream.
I’m not a lawyer, but even grief, aka pain and suffering, associated with unrealized losses (unsold shares) is not grounds for a civil lawsuit. But I hear you loud and clear. If things go south, I’m gonna have to move the wife and lab to the Cloud Forest west of Quito and buy some pigs and chickens to keep expenses down. I seriously doubt that will happen. A worst case, the BO price is lower than expected, but everyone is still made whole, and then some.
To be clear, the issue is unrealized losses vs. realized losses.
Yes, that’s a more fitting analogy. Great game.
"cc: John Henry". Nice finishing touch.
Good question. I wish I knew, but of course, no one knows what the SP will be when the official TLD is released and the journal article is published, nor how far the SP will fall when the next hit piece arrives. But I have a suspicion that the recent academic presentation will not have aided AF and his criminal gang's next move. There are too many unknown variables to make a convincing prediction. For example, a whale could come in at some point and start propping up the SP like Neil Woodford did way back when. But your scenario of having to live with SPs under $2 until est. approval 1Q 2023 doesn't seem far-fetched either, and it just may be how things play out. I can live with that, too, as long as we continue to steadily march towards approval. This possibility is why I am simply focusing on BLA submissions and approval by the first RA. Slinging mud in the interim is easy, but I honestly don't see anyone on this board doing a better job. If anything, NWBO would already be out of business if some of these posters were at the helm. Personally, I may sell a few shares here and there to keep my own lights on, but I'm basically holding until a few years down the road, whether it be via partnership, BO, or going it alone. Each of us deals with this stressful situation in our own way. Some need to constantly criticize management and vent here on this board, and I get that. Personally, I pray a lot for Linda Powers and invite everyone else here to do the same if so inclined. This is a spiritual battle just as much as it is anything else in my view, and she's up against a formidable evil force, pure and simple. However, God is way more powerful than those fools. I am sure many of the cancer patients, their families, and their oncologists are hoping and praying for Linda and DCVax-L's approval ASAP. Anyway, that's how I deal with all this stuff. For me it's the only way to make a contribution, be at peace, and be confident that our prayers will be answered. God's will be done. Best wishes.
Yes, but LP was strategic in going ahead with the academic presentation of trial results. When NWBO releases the official TLD, along with the journal article, the ensuing short attack will have not have same devastating effect. Castle, fork, check, and checkmate.
You are going to worry yourself sick Bob. Look at it this way: four BLAs will be submitted and NWBO will not run out of funds before at least one of the RAs approves. So, in the end, we can be confident that cancer patients will have access to the vaccine and the market cap will true up eventually. All this other stuff in between now and then is fluff. Who knows, LP and the execs at Merck may have already agreed in principle on a BO.
Would you accept that the science will indirectly save the day? Because of the science, other factors will support NWBO's success, like partnerships or a buyout.
Please remove.
Thank you.
The link worked for me. Maybe try a different browser?
Thou dost yuyulalaoooo too much. —Shakespeare
…and 5/12 is fifteen days after the originally planned ship date of 4/27, which for the upcoming publication would be the longest time frame between planned and actual ship dates. Given the fact that actual is usually before the planned ship date, one can’t help but wonder if, and hope that, this is related to NWBO’s long-awaited journal article.
VNDM’s 60000 ask at $1.50 looks good.
Yep, and Judge too.
Unless I'm missing something, I sincerely hope, at the very least, that NWBO discusses DCVax-L TLD (along with a possible DCVax-Direct update) at ASCO/IET, and if TLD is not released prior to the ASM announcement and proxy vote for additional shares, then they probably have more loans lined up. Otherwise, the ASM would have to be postponed until after June.
PM, I’ll have to clear it with the others in casting, but if you’re right, you’ll be given the option to play yourself in Seasons 6 & 7.
kabunushi, okay, let’s compromise, how about Rowan Atkinson?
No, James Woods hands down :)
Odoggy, I'm partial to the MD Anderson Cancer Center in Houston. They provided excellent medical and patient care for my wife who was diagnosed with cervical cancer in 2014. They saved her life. Also, the Jesse James Rotary House, managed by Marriott, is an adjacent property connected to the main medical complex building via an enclosed skybridge with free golf cart shuttles for patients and families if you don't want to walk. The Rotary House also has free shuttles to nearby Rice Village for shopping, restaurants, groceries, etc. That said, I don't know if they are tops in the USA for your loved one's type of cancer. God bless, V.
Pedes, ASCO 2022 is scheduled for June 3-7 in Chicago.
M2P, correct me if I’m wrong, but the goal is that DCVax-L will treat all operable malignant tumors and Direct all inoperable, so the former wouldn’t be a small market.
iwasadiver opined the same awhile back. I think you guys may be on to something.
It’s been posted that Cofer Black (et. al) was sued twice.
pfelg, you were close, but a little more time is needed until the pps reaches $2. As OTLK management has stated, the BLA should be completed by end of 1Q 2022, or any day now, and the corresponding PR should also boost the share price with FDA approval being very possible before the end of the year. Hopefully, that momentum will be maintained headed into 2023.
Cap, this is an interesting angle on the issue:
flipper44, not only smart, but funny too. thank you for your contribution.